Nanjing Legend Biotech CAR-T Patent, GPC2 Cancer Immunotherapy
Summary
The USPTO granted Patent US12606635B2 to Nanjing Legend Biotech Co., Ltd. covering GPC2-specific antibodies, antigen binding fragments, and chimeric antigen receptor (CAR) constructs for cancer immunotherapy. The patent encompasses T cells engineered with the disclosed CAR constructs. The application (No. 17910608) was filed March 12, 2021, and contains 19 claims.
What changed
The USPTO has granted Patent US12606635B2 to Nanjing Legend Biotech Co., Ltd., providing exclusive intellectual property rights to GPC2-specific antibodies and CAR constructs for binding glypican-2 (GPC2) in cancer immunotherapy applications.
For biotechnology and pharmaceutical companies engaged in CAR-T cell therapy development, this patent establishes a freedom-to-operate consideration around GPC2-targeting constructs. Researchers and developers working in pediatric or solid-tumor immunotherapy may need to evaluate potential licensing or design-around options for GPC2-targeted approaches.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
Grant US12606635B2 Kind: B2 Apr 21, 2026
Assignee
Nanjing Legend Biotech Co., Ltd.
Inventors
Wang Zhang, Jintao Guo, Fengyuan Tang, Shuai Yang, Yuanyuan Peng, An Tang, Xiaojie Tu, Yunlei Liu, Shu Wu
Abstract
The present application provides GPC2-specific antibodies and antigen binding fragments thereof. A chimeric antigen receptor (CAR) that specifically binds glypican-2 (GPC2) comprising a GPC2-specific antibody, a transmembrane domain, and an intracellular signaling domain. T cells comprising the disclosed CAR constructs can be used for cancer immunotherapy.
CPC Classifications
C07K 16/3053 C07K 14/5418 C07K 14/5443 C07K 14/70507 C07K 14/7051 C07K 14/70521 C07K 14/70578 C07K 16/18 C07K 16/3084 C07K 2317/24 C07K 2317/31 C07K 2317/35 C07K 2317/52 C07K 2317/565 C07K 2317/569 C07K 2317/92 C07K 2319/02 C07K 2319/03 C07K 2319/33 C07K 14/47 C07K 2317/22 C07K 2317/30 C07K 2317/33 C07K 2317/56 C07K 2317/73 C07K 2317/76 C07K 16/30 A61K 31/454 A61K 35/17 A61K 38/177 A61K 38/1774 A61K 38/2046 A61K 38/2086 A61K 39/3955 A61K 39/39558 A61K 40/11 A61K 40/31 A61K 40/4261 A61K 2039/505 A61K 2239/31 A61K 2239/38 A61K 2239/47 A61K 2239/55 A61K 2039/54 A61K 2039/55 A61P 11/00 A61P 25/00 A61P 35/00 C12N 5/0636 C12N 2501/2302 C12N 2502/30
Filing Date
2021-03-12
Application No.
17910608
Claims
19
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.